Natural products in pursuing novel therapies of nonalcoholic fatty liver disease and steatohepatitis

Drug Discov Today. 2023 Mar;28(3):103471. doi: 10.1016/j.drudis.2022.103471. Epub 2023 Jan 5.

Abstract

Nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) are hepatic manifestations of systemic metabolic dysfunction, which affect one-quarter of the adult population worldwide as estimated, and exhibit high risk in progressing to hepatic fibrosis, cirrhosis, and hepatocellular carcinoma. Current drug discovery focuses on modifying homeostasis of lipids, carbohydrates, and cholesterol, as well as inhibiting inflammation and fibrogenesis. Many natural products show promising activities on various molecular targets involving these mechanisms; however, they have not been fully exploited. Since some compounds are components of healthy food, they may be employed in chemoprevention as adjuvants to lifestyle modification, while natural products such as alkaloids and sesquiterpenoids could serve as promising starting points for structural modifications and deserve further development.

Keywords: FXR; NAFLD; NASH; drug discovery; natural products.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biological Products* / therapeutic use
  • Humans
  • Liver / metabolism
  • Liver Cirrhosis / metabolism
  • Liver Neoplasms* / pathology
  • Non-alcoholic Fatty Liver Disease* / metabolism

Substances

  • Biological Products